Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinblastine Sulfate

FDA-approved product (injectable, injection), marketed as Velban, Vinblastine Sulfate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vinblastine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Classic Hodgkin lymphoma
  • Fungal infectious disease
  • Hodgkins lymphoma
  • Lymphoid neoplasm
  • Lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinblastine Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinblastine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease

    NCT00002714 · start 1995-04

    Registered record
    Registry ID
    NCT00002714
    Conditions
    Lymphoma
    Interventions
    bleomycin sulfate; Stanford V regimen; doxorubicin hydrochloride; etoposide; mechlorethamine hydrochloride; prednisone; vinblastine sulfate; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1995-04
    Completion
    2001-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionbleomycin sulfate; Stanford V regimen; doxorubicin hydrochloride; etoposide +5 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

    NCT00002823 · start 1995-02

    Registered record
    Registry ID
    NCT00002823
    Conditions
    Lung Cancer
    Interventions
    cisplatin; etoposide; vinblastine sulfate; vindesine; vinorelbine tartrate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-02
    Completion
    Not recorded
    Enrolment
    3,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventioncisplatin; etoposide; vinblastine sulfate; vindesine +2 more
    PhasePhase 3
    Registry statusCompleted

  • Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

    NCT00002561 · start 1994-01-25

    Registered record
    Registry ID
    NCT00002561
    Conditions
    Hodgkin Lymphoma
    Interventions
    bleomycin sulfate; dacarbazine; doxorubicin hydrochloride; vinblastine; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1994-01-25
    Completion
    2012-01-06
    Enrolment
    405

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    Interventionbleomycin sulfate; dacarbazine; doxorubicin hydrochloride; vinblastine +1 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

    NCT00002715 · start 1989-04

    Registered record
    Registry ID
    NCT00002715
    Conditions
    Lymphoma
    Interventions
    Bleomycin sulfate; Stanford V regimen; Doxorubicin hydrochloride; Etoposide; Mechlorethamine hydrochloride; Prednisone; Vinblastine; Vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1989-04
    Completion
    2015-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionBleomycin sulfate; Stanford V regimen; Doxorubicin hydrochloride; Etoposide +4 more
    PhasePhase 2
    Registry statusCompleted

  • Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

    NCT00000626

    Registered record
    Registry ID
    NCT00000626
    Conditions
    HIV Infections; Hodgkin's Disease
    Interventions
    Vinblastine sulfate; Dacarbazine; Filgrastim; Bleomycin sulfate; Doxorubicin hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1999-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hodgkin's Disease
    InterventionVinblastine sulfate; Dacarbazine; Filgrastim; Bleomycin sulfate +1 more
    PhasePhase 2
    Registry statusCompleted